| Status | In progress |
| Technology type | Medicine |
| Decision | Selected |
| Reason for decision | Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources |
| Further information | Following a request received from the company, NICE will be undertaking an appraisal of SQ HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites (review of TA834) [ID6280]. The appraisal is expected to start during early July 2023 with a consultation on the draft scope. It is then anticipated that the final scope will be released along with an invitation to participate in the appraisal during late-August 2023. The deadline for submissions is expected in approximately late-October 2023. |
| Process | STA Standard |
| ID number | 6280 |
Provisional Schedule
| Expected publication | 12 February 2025 |
Project Team
| Project lead | Vonda Murray |
Email enquiries
- If you have any queries please email tateam3@nice.org.uk
Stakeholders
| Companies sponsors | ALK-Abello (SQ HDM SLIT) |
| Others | Department of Health and Social Care |
| Health Technology Wales (HTW) | |
| NHS England | |
| Welsh Government | |
| Patient carer groups | Allergy UK |
| Asthma + Lung UK | |
| Fifth Sense | |
| Anaphylaxis UK | |
| Professional groups | Association of Respiratory Nurse Specialists |
| British Paediatric Allergy, Immunity and Infection Group (BPAIIG) | |
| British Society for Allergy & Clinical Immunology | |
| British Thoracic Society | |
| British Society for Immunology Clinical Immunology Professional Network (BSI-CIPN) | |
| ENT UK | |
| National Heart and Lung Institute | |
| Royal College of Physicians | |
| Royal Society of Medicine - Allergy and Immunology Section | |
| Comparator companies | AstraZeneca (benralizumab, tezepelumab) - (confidentiality agreement not signed, not participating) |
| GlaxoSmithKline (mepolizumab) - (confidentiality agreement not signed, not participating) | |
| Novartis (omalizumab) - (confidentiality agreement not signed, not participating) | |
| Sanofi (dupilumab) - (confidentiality agreement not signed, not participating) | |
| Teva (reslizumab) - (confidentiality agreement not signed, not participating) | |
| Evidence review group | Centre for Reviews and Dissemination and Centre for Health Economics – York |
| General commentators | All Wales Therapeutics and Toxicology Centre |
| British National Formulary | |
| Department of Health - Northern Ireland | |
| Healthcare Improvement Scotland | |
| Medicines and Healthcare products Regulatory Agency | |
| Scottish Medicines Consortium | |
| Welsh Health Specialised Services Committee | |
| Relevant research groups | National Institute for Health Research |
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 10 December 2024 | Declaration of interests |
| 12 November 2024 | Committee meeting: 2 |
| 13 June 2024 - 16 September 2024 | Draft guidance |
| 14 May 2024 | Committee meeting: 1 |
| 14 May 2024 | Declaration of interests |
| 23 August 2023 | Invitation to participate |
| 23 August 2023 | In progress. In progress |
| 21 June 2023 | Awaiting development. Following a request received from the company, NICE will be undertaking an appraisal of SQ HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites (review of TA834) [ID6280]. The appraisal is expected to start during early July 2023 with a consultation on the draft scope. It is then anticipated that the final scope will be released along with an invitation to participate in the appraisal during late-August 2023. The deadline for submissions is expected in approximately late-October 2023. |
For further information on our processes and methods, please see our CHTE processes and methods manual